Skip to main content
SpringerLink
Log in
Book cover

Interferons pp 116–131Cite as

Treatment Strategies in Multiple Myeloma: Biotherapy with Interferons

  • Conference paper

  • 94 Accesses

Abstract

Over 25 000 new cases of multiple myeloma are diagnosed in Europe and the United States each year. The incidence varies among countries, from one per 100 000 persons in China to approximately four per 100 000 in the United States and most Western industrialized countries. Blacks are affected twice as often as Caucasians, and men more often than women. Multiple myeloma is clearly an age-dependent disease, with affected individuals having a mean age of approximately 60 years at diagnosis. Although survival is highly variable, the majority of patients with multiple myeloma will succumb to the disease or its complications within 3 years. While there is no cure for this cancer, newer treatments have been developed in the last decade that prolong the disease-free period and allow patients to enjoy a more normal, productive, and pain-free life for longer than was previously possible.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334–342

    PubMed  CAS  Google Scholar 

  2. Case DC Jr., Lee BJ III, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63: 897–903

    Article  PubMed  Google Scholar 

  3. Durie BGM, Dixon DO, Carter S et al (1986) Improved survival duration with combination chemotherapy induction for multiple myeloma: Southwest Oncology Group study. J Clin Oncol 4: 1227–1237

    PubMed  CAS  Google Scholar 

  4. Quesada JR, Alexanian R, Hawkins M et al (1986) Treatment of multiple myeloma with recombinant α-interferon. Blood 67: 275–278

    PubMed  CAS  Google Scholar 

  5. Ludwig H, Cortelezzi A, Scheithauer W et al (1986) Recombinant interferon alpha-2C versus poly-chemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 22: 1111–1116

    Article  PubMed  CAS  Google Scholar 

  6. Mellstedt H, Österborg A, Björkholm M et al (1991) Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Br J Haematol 79 [Suppl 1]: 21–25

    Article  PubMed  Google Scholar 

  7. Österborg A, Björkholm M, Björeman M et al (1993) Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednison in the treatment of multiple myeloma stages II and III: a randomized study from the myeloma group of central Sweden. Bloody 81: 1428–1434

    Google Scholar 

  8. Ludwig H, Cohen AM, Huber H et al (1991) Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer 27 [Suppl 40]: 40–45

    Google Scholar 

  9. Cooper MR, Dear K, McIntyre OR et al (1993) A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a cancer and leukemia group B study. J Clin Oncol 11: 155–160

    PubMed  CAS  Google Scholar 

  10. Kyle RA (1993) Newer approaches to the management of multiple myeloma. Cancer 72–11 [Suppl]: 3489–3494

    Article  PubMed  CAS  Google Scholar 

  11. Attal M, Harousseau JL, Stoppa AM et al (1994) High dose therapy in multiple myeloma: a prospective randomized study of the“Intergroupe Francais du Myelome.” International Workshop on Multiple Myeloma

    Google Scholar 

  12. Mandelli F, Awisati G, Amadori S et al (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430–1434

    Article  PubMed  CAS  Google Scholar 

  13. Westin J, Rödjer S, Turesson I et al (1995) Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 89: 561–568

    Article  PubMed  CAS  Google Scholar 

  14. Ludwig H, Cohen AM, Polliack A et al (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 6: 467–476

    PubMed  CAS  Google Scholar 

  15. Browman S, Rubin I, Walker D et al (1994) Interferon α-2b (IFN) maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma (PCM): results of a randomized trial. Proc Am Soc Clin Oncol 13: 408

    Google Scholar 

  16. Salmon SE, Crowley JJ, Grogan TM et al (1994) Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 12: 2405–2414

    PubMed  CAS  Google Scholar 

  17. Peest D, Deicher H, Coldewey R et al (1990) Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. Onkologie 13: 458–460

    Article  PubMed  CAS  Google Scholar 

  18. Peest D, Deicher H, Coldewey R et al (1995) A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A: 146–151

    Article  PubMed  CAS  Google Scholar 

  19. Cunningham D, Powles R, Malpas JS et al (1993) A randomised trial of maintenance therapy with INTRON-a following high dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 12: 364

    Google Scholar 

  20. Ganjoo RK, Johnson PWM, Evans ML et al (1993) Recombinant interferon-alpha2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma. Hematol Oncol 11: 179–186

    Article  PubMed  CAS  Google Scholar 

  21. San Miguel JF, Moro M, Blade J et al (1991) Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. Eur J Cancer 27 [Suppl 4]: S48-S49

    Google Scholar 

  22. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330: 484–489

    Article  PubMed  CAS  Google Scholar 

  23. Oken MM (1994) Strategies for managing multiple myeloma. Contemp Oncol 14–17

    Google Scholar 

  24. Cunningham D, Paz-Ares L, Milan S et al (1994) High -dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12: 759–763

    PubMed  CAS  Google Scholar 

  25. Hussein M (1994) Multiple myeloma: an overview of diagnosis and management. Cleve Clin J Med 61: 285–298

    PubMed  CAS  Google Scholar 

  26. MacLennan IC, Chapman C, Dunn J, Kelly K (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 339: 200–205

    Article  PubMed  CAS  Google Scholar 

  27. Samson D (1994) Multiple myeloma: current treatment. Grad Med J 70: 404–410

    Article  CAS  Google Scholar 

  28. Fermand J-P, Chevret S, Ravaud P et al (1993) High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 82: 2005–2009

    PubMed  CAS  Google Scholar 

  29. Wisløff F (1993) IV. International Workshop on Multiple Myeloma

    Google Scholar 

  30. Mellstedt H, Ahre A, Bjorkholm M et al (1979) Interferon therapy in myelomatosis. Lancet 1: 245–248

    Article  PubMed  CAS  Google Scholar 

  31. Gutterman JU, Blumenschein GR, Alexanian R et al (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399–406

    PubMed  CAS  Google Scholar 

  32. Alexanian R, Gutterman J, Levy H (1982) Treatment of multiple myeloma. Clin Haematol 11: 211–220

    PubMed  CAS  Google Scholar 

  33. Ahre A, Bjorkholm M, Mellstedt H et al (1984) Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 68: 1331–1338

    PubMed  CAS  Google Scholar 

  34. Ahre A, Bjorkholm M, Osterborg A et al (1988) High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma - a pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 41: 123–130

    Article  PubMed  CAS  Google Scholar 

  35. Costanzi JJ, Cooper MR Scarffe JH et al (1985) Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 3: 654–659

    PubMed  CAS  Google Scholar 

  36. Wagstaff JK, Loynds P, Scarffe JH (1985) Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cancer Treat Rep 69: 495–498

    PubMed  CAS  Google Scholar 

  37. Costanzi JJ (1985) Proceedings of the Serono Symposium. Raven

    Google Scholar 

  38. Cooper MR (1988) Interferons in the management of multiple myeloma. Semin Oncol 15 [Suppl 5]: 21–25

    PubMed  CAS  Google Scholar 

  39. Balkwill FR, Moodie EM (1984) Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 44: 904–908

    PubMed  CAS  Google Scholar 

  40. Cooper MR, Fefer A, Thompson J et al (1986) Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I—II trial. Cancer Treat Rep 70: 473–476

    PubMed  CAS  Google Scholar 

  41. Oken MM, Kyle RA (1991) Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. Semin Oncol 18 [Suppl 7]: 30–32

    PubMed  CAS  Google Scholar 

  42. Westin J, Cortelezz A, Hjorth M, Rodjer S, Turesson I, Zador (1990) Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study. Eur J Cancer 27 [Suppl 4]: 45–48

    Google Scholar 

  43. Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161–166

    Article  PubMed  CAS  Google Scholar 

  44. Fossa SD, Gunderson R, Moe B (1990) Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate - a phase II study. Cancer 65: 2451–2454

    Article  PubMed  CAS  Google Scholar 

  45. Alexanian R, Barlogie B, Gutterman J (1990) Alpha interferon combination therapy for multiple myeloma. IFN therapy in B-cell malignancies (Abstr). 5th Hannover Interferon Workshop, 43

    Google Scholar 

  46. Alexanian R, Barlogie B, Gutterman J (1991) Alpha-interferon combination therapy of resistant myeloma. J Clin Oncol 14: 188–192

    Article  CAS  Google Scholar 

  47. Gertz MA, Kalish LA, Kyle RA (1994) A phase III study comparing VAD chemotherapy with VAD plus recombinant α-2 interferon in refractory or relapsed multiple myeloma (Abstr). Proc Am Soc Clin Oncol 13: 375

    Google Scholar 

  48. San Miguel JF, Moro M, Blade J et al (1990) Combination of interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 8: 185–189

    Article  Google Scholar 

  49. Ohno R (1987) Interferons in the treatment of multiple myeloma. Int J Cancer 1 [Suppl]: 14–20

    Article  CAS  Google Scholar 

  50. Casassus Ph (1994) International conference: multiple myeloma, from biology to therapy (Abstr). Mulhouse, 69

    Google Scholar 

  51. Joshua DE, Penny R, Baldwin R et al (1994) The study of combination therapy plus or minus Roferon A in multiple myelomas (Abstr). Blood 84 [Suppl 1]: 179a

    Google Scholar 

  52. Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A (1990) Alpha-2a-interferon/ melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 76: 365–368

    Article  PubMed  CAS  Google Scholar 

  53. Corrado C, Pavlovsky S, Saslasky J et al (1989) Randomized trial comparing melphalan-prednisone with or without recombinant alpha-2 interferon (r-alpha2IFN) in multiple myeloma (Abstr). Proc Am Soc Clin Oncol 8: 258

    Google Scholar 

  54. Garcia-Larana J, Steegmann JL, Perez-Oteyza J et al (1992) Treatment of multiple myeloma with melphalan/prednisone (MP) versus melphalan/prednisone and alpha-2b-interferon (MP-IFN). Results of a Cooperative Spanish Group (Abstr). Cong Int Soc Haematol 24: 301

    Google Scholar 

  55. Vela Ojeda J, Vazquez V, Garcia Ruiz EM et al (1993) A randomized clinical trial comparing chemotherapy with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma (Abstr). IV. International Workshop on Multiple Myeloma, Rochester, 150

    Google Scholar 

  56. Aitchison R, Williams A, Schey S, Newland AC (1993) A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma. Leuk Lymphoma 9: 243–246

    Article  PubMed  CAS  Google Scholar 

  57. Capinist G, Sapirano M, Damasio EE et al (1993) Is IFN helpful in the treatment of multiple myeloma? Preliminary results of a multicenter study of Italian NHLCSG (Abstr). Proc Am Soc Clin Oncol 12: 407

    Google Scholar 

  58. McSweeney EN, Topias JS, Blackman G, Goldstone AH, Richards JD (1993) Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol (R Coll Radiol) 5: 378–383

    CAS  Google Scholar 

Download references

Authors
  1. H. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Carlo Aul  & Wolfgang Schneider  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Ludwig, H. (1997). Treatment Strategies in Multiple Myeloma: Biotherapy with Interferons. In: Aul, C., Schneider, W. (eds) Interferons. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60411-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60411-9_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61051-9

  • Online ISBN: 978-3-642-60411-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation